Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of β-transducin repeat-containing protein

Molecular Pharmacology

Volumn 76, Issue 1, 2009, Pages 47-57

  Wei, Shuo ^a   Chuang, Hsiao Ching ^a   Tsai, Wan Chi ^b   Yang, Hsiao Ching ^c   Ho, Shiuh Rong ^d   Paterson, Andrew J ^e   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (4 HYDROXY 3 TRIFLUOROMETHYLBENZYLIDENE) 3 (1 METHYLCYCLOHEXYL)THIAZOLIDINE 2,4 DIONE; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CIGLITAZONE; DELTA 2CG; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; SERINE; SMALL INTERFERING RNA; THIAZOLE DERIVATIVE; THREONINE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UBIQUITINATION; UPREGULATION;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE, TUMOR; FEMALE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MAP KINASE KINASE 1; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SP1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 67649866042     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.055376     Document Type: Article

References (35)

1. Benasciutti E, Pagès G, Kenzior O, Folk W, Blasi F, and Crippa MP (2004) MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104:256-262. (Pubitemid 38879866)
2. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, Mukhtar H, and Spiegelman VS (2006) Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 281:19320-19326. (Pubitemid 44035437)
3. Bonello MR and Khachigian LM (2004) Fibroblast growth factor-2 represses platelet-derived growth factor receptor-α (PDGFR-α) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-α promoter. J Biol Chem 279:2377-2382. (Pubitemid 38114220)
4. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, and Filetti S (2002) Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2:35. (Pubitemid 38851286)
5. Chu S and Ferro TJ (2006) Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 signaling pathway for gene regulation. Am J Physiol Lung Cell Mol Physiol 291:L983-L992. (Pubitemid 44772061)
6. 2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell 19:1139-1151.
7. Fiser A, Do RK, and Sali A (2000) Modeling of loops in protein structures. Protein Sci 9:1753-1773.
8. Frescas D and Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438-449. (Pubitemid 351744963)
9. Han I and Kudlow JE (1997) Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 17:2550-2558. (Pubitemid 27175136)
10. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, and Lu D (2008) Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 17:1648-1652.
11. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, and Xie K (2004) A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 21:755-764.
12. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Haruma K, Kajiyama G, and Tahara E (1992) The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 189: 1342-1348. (Pubitemid 23041306)
13. Latres E, Chiaur DS, and Pagano M (1999) The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18:849-854. (Pubitemid 29086261)
14. Liétard J, Musso O, Théret N, L'Helgoualc'h A, Campion JP, Yamada Y, and Clément B (1997) Sp1-mediated transactivation of LamC1 promoter and coordinated expression of laminin-gamma1 and Sp1 in human hepatocellular carcinomas. Am J Pathol 151:1663-1672. (Pubitemid 27527929)
15. Mackerell AD Jr (2004) Empirical force fields for biological macromolecules: overview and issues. J Comput Chem 25:1584-1604.
16. Nakayama KI and Nakayama K (2005) Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16:323-333. (Pubitemid 40504221)
17. Samson SL and Wong NC (2002) Role of Sp1 in insulin regulation of gene expression. J Mol Endocrinol 29:265-279. (Pubitemid 36024543)
18. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, and Xie K (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61:4143-4154. (Pubitemid 32720983)
19. Slack JK, Catling AD, Eblen ST, Weber MJ, and Parsons JT (1999) c-Raf-mediated inhibition of epidermal growth factor-stimulated cell migration. J Biol Chem 274:27177-27184. (Pubitemid 129520245)
20. Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS, and Stephanou A (2008) ERK and the F-box protein βTRCP target STAT1 for degradation. J Biol Chem 283:16077-16083.
21. Su K, Roos MD, Yang X, Han I, Paterson AJ, and Kudlow JE (1999) An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J Biol Chem 274:15194-15202. (Pubitemid 129518859)
22. Su K, Yang X, Roos MD, Paterson AJ, and Kudlow JE (2000) Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem J 348:281-289. (Pubitemid 30345199)
23. Tempé D, Casas M, Karaz S, Blanchet-Tournier MF, and Concordet JP (2006) Multisite protein kinase A and glycogen synthase kinase 3beta phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP. Mol Cell Biol 26:4316-4326. (Pubitemid 43788030)
24. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, and Xie K (2003) Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9:6371-6380. (Pubitemid 38031822)
25. Wei S, Lin LF, Yang CC, Wang YC, Chang GD, Chen H, and Chen CS (2007) Thiazolidinediones modulate the expression of β-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor γ. Mol Pharmacol 72:725-733. (Pubitemid 47347307)
26. Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ, Lai MD, and Chen CS (2008) A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem 283:26759-26770.
27. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehr R, Shi Y, Harper JW, et al. (2008) SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452:370-374.
28. Wierstra I (2008) Sp1: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 372:1-13.
29. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, and Pavletich NP (2003) Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 11:1445-1456. (Pubitemid 36776532)
30. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, Lin CC, and Chen CS (2007) Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 67:3229-3238. (Pubitemid 46724861)
31. Yang CS, Yu C, Chuang HC, Chang CW, Chang GD, Yao TP, and Chen H (2005) FBW2 targets GCMa to the ubiquitin-proteasome degradation system. J Biol Chem 280:10083-10090. (Pubitemid 40395860)
32. Yang J, Wei S, Wang DS, Wang YC, Kulp SK, and Chen CS (2008) Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. J Med Chem 51:2100-2107.
33. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, and Xie K (2004) Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10:4109-4117. (Pubitemid 38812490)
34. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, and Xie K (2007) Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 110:2682-2690. (Pubitemid 350250337)
35. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, and Hung MC (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6:931-940. (Pubitemid 39359846)